compliancecitizenshipcollaborationsawardshistoryirelandcontactproductspraluent alirocumab injectioneylea aflibercept injectionarcalyst rilonacept injectionpipelineclinical leadershiponcologycardiovascular and metabolisminfectious diseasesinflammationophthalmologypainsciencescientific leadershipregeneron genetics centertarget discoverydrug candidate platformsprotein productionpublicationsscience educationregeneron science talent searchinvestors & mediamediapress releasesevents and presentationssec filingsfinancial informationstock informationcorporate governanceinvestor faqsinvestor contactcareers science to medicine when you are diagnosed with a serious disease life doesn t stop and neither will we . at regeneron we are driven by science and motivated by patients every step of the way . we are honored to announce the regeneron science talent search recognizing the next generation of groundbreaking minds . we know that science can change lives and we know that patients need new and improved treatment options . latest news oct 5 new survey reveals the widespread and serious impact of moderate to severe atopic dermatitis on people living with the disease more oct 1 regeneron and sanofi announce positive dupixent dupilumab phase 3 atopic dermatitis data published in the new england journal of medicine more sep 26 regeneron and sanofi announce dupilumab biologics license application accepted for priority review by u.s. fda more our pipeline striving for new therapies that improve patients lives we have an extensive pipeline of investigational product candidates that are progressing through all stages of human clinical trials . our product candidates address many serious medical conditions including cancer eye diseases inflammatory diseases pain cardiovascular diseases and allergic conditions . our products praluent alirocumab injection learn more about praluent download prescribing information eylea aflibercept injection learn more about eylea download prescribing information arcalyst rilonacept injection learn more about arcalyst download prescribing information our people discovering and developing drugs to help patients takes years of hard work . there are no shortcuts in this business but we always believed that we could succeed . leonard schleifer md phd president and ceo our people regeneron is a place where new ideas are welcome . the environment fosters growth and progress that allows us to produce a product that meets the highest quality standards . shazad suchit quality control analyst iii our people everything that we ve been doing for 25 years interconnects . we re building on the foundation of those early ideas and taking them to the next level . george yancopoulos md phd founding scientist president regeneron laboratories and chief scientific officer our people our drug development programs are propelled by the desire to address unmet medical needs and all our work is done with the utmost integrity . sumathi sivapalasingam director clinical sciences translational medicine our promise integrity is a core value at regeneron and lies at the heart of everything we do . learn more about our corporate citizenship ethics and compliance . companymanagementboard of directorsethics and compliancecitizenshipcollaborationsawardshistoryirelandcontactproductspraluent alirocumab injectioneylea aflibercept injectionarcalyst rilonacept injectionpipelineclinical leadershiponcologycardiovascular and metabolisminfectious diseasesinflammationophthalmologypainsciencescientific leadershipregeneron genetics centertarget discoverydrug candidate platformsprotein productionpublicationsscience educationregeneron science talent searchinvestors & mediamediapress releasesevents and presentationssec filingsfinancial informationstock informationcorporate governanceinvestor faqsinvestor contactcareers follow us twitter linkedin terms of use privacy policy social media terms of engagement careers contact us copyright 2016 regeneron pharmaceuticals inc. all rights reserved . as our company grows so does our commitment to future scientists . we are honored to announce the regeneron science talent search recognizing the next generation of groundbreaking minds . learn more x close now approved in the united states . july 2015 ali 0937 click to close hello wnyc listener we are a science driven biotechnology company developing medicines for people with serious diseases . read more about how we are working to improve patients lives our products our pipeline our news careers at regeneron follow us click to close hello wnyc listener we are a science driven biotechnology company developing medicines for people with serious diseases . read more about how we are working to improve patients lives our products our pipeline our news careers at regeneron follow us close video close window close window form content here please